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 Approximately 5-10% of cancers are thought to be hereditary, caused by 
pathogenic variants in genes associated with inherited cancer syndromes. Previvors, 
individuals who have a higher predisposition to cancer due to genetic or other risk 
factors, have specific healthcare and psychological needs that may be better served by a 
specialized management clinic. This study compared the experiences of previvors who 
had access to a specialized management clinic with those who did not, in order to better 
understand the unique needs of previvors. This study utilized a mixed methods design 
including an online survey (N=26) and semi-structured phone interview (N=6). Overall, 
previvors with access to a specialized management expressed a reduction in stress level 
(N=5), expedited necessary medical care (N=2), access to a simplified clinical process 
(N=5), and provision of information needed to make informed decisions regarding their 
medical care (N=8). Previvors who did not have access to a specialty clinic described 
challenges with finding information about their risk (N=4), receiving care from general 
practitioners (N=3), and having questions unanswered by healthcare providers (N=6), 
further supporting previous literature that investigated the nuanced care required by 
previvors. Previvors without access to a management clinic desired a team of specialists 
familiar with genetics, a forum to ask questions, and a clinic that would ensure their care 
meets the current recommendations. This study demonstrates the need for specialized 
management clinics designed with previvors’ needs in mind in order to provide these 
patients with the most appropriate care. 
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CHAPTER 1: BACKGROUND AND LITERATURE REVIEW 
1.1 Hereditary Cancer 
 Approximately 5-10% of cancers are thought to be hereditary. Hereditary cancer 
is caused by mutations in genes associated with hereditary cancer syndromes, and a 
pathogenic mutation results in a significantly increased risk for cancer development 
compared to that of the average population (Senter & Hatfield, 2016). Mutations that 
cause hereditary cancer syndromes are identified through the use of genetic testing, 
specifically testing that targets oncogenes and tumor suppressor genes, genes associated 
with regulation of cell growth and hereditary cancer (Dekanek et al., 2019). Once a 
pathogenic mutation has been identified, it is recommended that the patient pursue 
management specific to their cancer risks, often as directed by the guidelines established 
by the National Comprehensive Cancer Network (NCCN), a society recognized in the 
medical community to be an authority on cancer care (NCCN, 2020). 
 There are a large number of genes associated with hereditary cancer. This study 
encompassed individuals with mutations in ATM, BRCA1, BRCA2, CDH1, CHEK2, 
PALB2, PTEN, and TP53. While these genes are mainly associated with breast cancer, 
mutations in them also carry other cancer risks. In addition, these genes have specific 
management recommendations established by NCCN that aid in patient care. The cancer 
risks for each gene are shown in Table 1.1 below (adapted from GeneReviews (2016); 
National Comprehensive Cancer Network (NCCN), 2020).
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Table 1.1 High-Risk Breast Cancer Genes and Associated Cancer Risks 
   Gene Cancer Risks 








Pancreatic (≤ 5%) 
BRCA2 Breast, with predisposition to ER+ disease (>60%)  
Ovarian (13-29%) 




CDH1 Breast, with predisposition to lobular disease (41-60%) 
Diffuse gastric 















TP53 Breast (>60%) 
Pancreatic (5-10%) 









1.2 Genetic Testing Recommendations for Hereditary Cancer 
 Genetic testing for hereditary cancer syndromes is recommended for individuals 
who meet certain criteria as determined by NCCN. One example of this criteria is the 
NCCN Testing Criteria for High-Penetrance Breast and/or Ovarian Cancer Susceptibility 
Genes. If criteria are met and no known familial mutation has been identified, providers 
should consider comprehensive testing for the patient with a multi-gene panel (NCCN, 
2020).  NCCN (2020) recommends genetic testing for hereditary breast and ovarian 
cancer for the following indications, listed in Table 1.2 below (adapted from NCCN, 
2020). 
Table 1.2 NCCN Testing Criteria for High-Penetrance Breast/Ovarian Cancer 
Susceptibility Genes 
NCCN Testing Criteria for High-Penetrance Breast/Ovarian Cancer 
Susceptibility Genes 
1. Any blood relative with a pathogenic/likely pathogenic variant in a cancer 
susceptibility gene 
2. Personal history of breast cancer under age 45 or age 46-50 with a second breast 
cancer at any age or at least one close relative with breast, ovarian, pancreatic, or 
prostate cancer at any age 
3. Personal history of triple negative breast cancer at age 60 or younger 
4. Personal history of breast cancer at any age with Ashkenazi Jewish ancestry or a 
close relative with breast cancer under age 50, ovarian, pancreatic, or metastatic 
prostate cancer at any age 
5. Diagnosis of male breast cancer at any age 
6. Diagnosis of epithelial ovarian cancer (including fallopian tube cancer or peritoneal 
cancer) at any age 
7. Diagnosis of exocrine pancreatic cancer at any age 
8. Diagnosis of prostate cancer at any age with metastatic, intraductal/cribriform 
histology, or high- or very-high-risk group 
9. Diagnosis of prostate cancer of any NCCN risk group with Ashkenazi Jewish 
ancestry, one or more close relatives with breast cancer under age 50, ovarian, 
pancreatic, or metastatic, or intraductal/cribriform prostate cancer at any age, or 2 or 
more close relatives with either breast or prostate cancer (any grade) at any age 
10. A mutation was identified on tumor genomic testing that has clinical implications if 
identified in the germline 
11. Meets Li-Fraumeni Syndrome testing criteria, Cowden syndrome/PTEN hamartoma 
syndrome testing criteria 
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12. To aid in systemic therapy decision-making, such as for HER2-negative breast 
cancer 
13. An affected or unaffected individual with a first- or second- degree relative meeting 
any of the above  
14. An affected or unaffected individual who otherwise does not meet the criteria above 
but has a probability >5% of a BRCA1/2 pathogenic variant based on prior 
probability models (e.g., Tyrer-Cuzick, BRCAPro, Can Risk)  
 
1.3 Previvorship 
 By meeting the first or thirteenth criterion described above, and pursing testing 
for a known familial variant or because of a family history of cancer, individuals are 
learning of their previvor status (NCCN, 2020). The term previvor was initially coined by 
the advocacy group, Facing Our Risk of Cancer Empowered (FORCE), and is used to 
describe individuals “who have a much greater predisposition to cancer than individuals 
in the general population but who have not yet developed the disease” (Carvalho et al., 
2019, p. 1). Increase in the identification of previvors can be attributed to increased 
interest in genetic testing, increased testing of ovarian cancer patients who may be 
candidates for PARP (poly ADP-ribose polymerase) inhibitor therapies, and the 
identification of relatives of these patients who may be at risk for carrying these 
mutations (Carvalho et al., 2019). This greater susceptibility may be due to the presence 
of a pathogenic mutation in a hereditary cancer gene, increasing the risk for cancer, or 
could be caused by other factors including family history (Getachew-Smith et al., 2019). 
It has been recognized that individuals falling within the previvor category have “specific 
psychosocial and healthcare needs…to help them decide how to manage this substantial 
risk” (Mahon, 2014, p. 21). 
 Getachew-Smith et al. (2019) studied patients’ perceptions of the term previvor 
and whether or not that identity resonated with them. Although FORCE established a 
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definition for what constitutes a previvor, individuals who fall into that category had two 
main distinctions in their definition. One group identified previvors as those with a 
positive genetic test result, while the other group only considered previvors to be those 
that have undergone some form of risk reducing surgery, either mastectomy or 
oophorectomy. When assessing whether or not individuals accepted the term, they found 
that the majority accepted the label, claiming that the term previvor gave them a sense of 
community and validated their experience. However, some rejected the term due to its 
similarity to the word “survivor,” and felt that perhaps the label diminished the 
experience of cancer survivors. Some also felt that the term invoked fear, making it sound 
as if cancer was inevitable (Getachew-Smith et al., 2019). Although there is no clear 
consensus on the use of the term previvor, it is clear individuals within this category have 
unique challenges. 
1.4 Genetics-Based Management 
 Individuals with mutations in hereditary cancer genes have specific management 
recommendations established by NCCN, but recommendations differ slightly from gene 
to gene. In general, breast cancer screenings begin earlier than for women of average risk, 
and for some mutations, a risk-reducing surgery, such as a mastectomy or salpingo-
oophorectomy, may be considered. Because cancer risks vary from gene to gene, it is 
important to know the patient’s carrier status when determining a management plan. 
Table 1.3 outlines recommendations for each gene, adapted from the NCCN guidelines 




Table 1.3 NCCN Management Recommendations for Hereditary Cancer Predisposition 
Gene Management Recommendations 
ATM Annual mammogram, consider breast MRI at age 40 
Risk-reducing mastectomy or salpingo-oophorectomy based on family 
history 
Pancreatic cancer screening (MRCP and EUS) starting at age 50 if family 
history of pancreatic cancer 
BRCA1 Breast awareness at age 18 
Clinical breast exam every 6-12 months, beginning at age 25 
Annual breast MRI from age 25 to 29 
Annual mammogram with or without tomosynthesis from age 30 to 75 
Consider risk-reducing mastectomy 
Recommend salpingo-oophorectomy, typically between age 35-40 
BRCA2 Breast awareness at age 18 
Clinical breast exam every 6-12 months, beginning at age 25 
Annual breast MRI from age 25 to 29 
Annual mammogram with or without tomosynthesis from age 30 to 75 
Consider risk-reducing mastectomy  
Recommend salpingo-oophorectomy, no later than age 40-45 
CDH1 Annual mammogram, consider breast MRI at age 30 
Prophylactic gastrectomy between ages 18 and 40 and baseline endoscopy 
Risk-reducing mastectomy based on family history 
CHEK2 Annual mammogram, consider breast MRI at age 40 
Colonoscopy every 5 years, beginning at age 40, or 10 years prior to first-
degree relative’s age at diagnosis 
PALB2 Annual mammogram, consider breast MRI at age 30 
Discuss option of risk-reducing mastectomy 
Risk-reducing salpingo-oophorectomy based on family history 
Pancreatic cancer screening (MRCP and EUS) starting at age 50 if family 
history of pancreatic cancer 
PTEN Breast awareness at age 18 
Clinical breast exam every 6-12 months, starting at age 25 or 10 years before 
diagnosis of breast cancer in family (whichever comes first) 
Annual mammogram, consider breast MRI at age 30-35 (or 10 years before 
diagnosis in family) until age 75 
Discuss option of risk-reducing mastectomy 
Consider endometrial biopsy every 1-2 years, starting age 35 
Consider hysterectomy upon completion of childbearing 
Annual physical exam, starting age 18 (or 5 years prior to first cancer 
diagnosis) 
Annual thyroid ultrasound, starting age 7 
Colonoscopy starting age 35, every 5 years if negative (start earlier if family 
history) 
Consider renal ultrasound at age 40, every 1-2 years 
Routine dermatology evaluation 
Consider psychomotor assessment and brain MRI if symptoms present 
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TP53 Breast awareness at age 18 
Clinical breast exam every 6-12 months, starting age 20 
Breast MRI age 20-29, MRI and mammogram age 30-75 
Discuss risk-reducing mastectomy 
Physical exam and neurological evaluation in cancer survivors every 6-12 
months 
Colonoscopy and upper endoscopy every 2-5 years, starting age 25 (or 
earlier if family history) 
Annual dermatologic evaluation, starting age 18 
Annual whole-body MRI 
Annual brain MRI 
Pancreatic cancer screening (MRCP and EUS) starting at age 50 if family 
history of pancreatic cancer 
 
 
1.5 Management for Patients at High Risk of Breast Cancer 
 Some previvors may have a predisposition to cancer not due to a genetic 
mutation, but rather due to family history or other factors (Getachew-Smith et al., 2019). 
Several verified risk models exist to determine lifetime risk for breast cancer, including 
Tyrer Cuzick, Gail, BRCAPRO, Claus, and BOADICEA. These models take into account 
family history of breast and/or ovarian cancer, age, breast density, reproductive history, 
hormonal history, genetic testing, and history of abnormal breast imaging or pathology to 
calculate a lifetime risk for breast cancer (Monticciolo et al., 2018).  
Women with a lifetime risk of breast cancer greater than or equal to 20% as 
determined by these models are recommended to have additional screening, similar to 
that of individuals with a genetic mutation that increases breast cancer risk (Monticciolo 
et al., 2018). Table 1.4, below, adapted from NCCN (2021), outlines the recommended 





Table 1.4 NCCN High-Risk Breast Cancer Screening Guidelines 
High-Risk Management 
Breast awareness 
Clinical encounter every 6-12 months (not to be started before age 21) 
Annual screening mammogram 
• 10 years prior to age of youngest breast cancer diagnosis in family 
• Not to be started before age 30 
• Consider tomosynthesis 
Recommend annual breast MRI 
• 10 years prior to age of youngest breast cancer diagnosis in family 
• Not to be started before age 25 
Recommend risk-reducing strategies 
• Limit alcohol consumption 
• Increase physical activity 
• Weight control 
• Breastfeeding 
• Consider risk-reducing agents (tamoxifen, raloxifene, aromatase inhibitors) 
 
 Tamoxifen is a risk-reducing agent recommended for individuals at an increased 
risk for breast cancer. NCCN currently recommends women age 35 or older may take 20 
milligrams per day for five years and doing so can reduce breast cancer risk up to 49% 
(NCCN, 2020). For individuals who have a history of atypical hyperplasia, taking 
tamoxifen may reduce breast cancer risk by up to 89% (NCCN, 2020). Because of its 
efficacy, NCCN recommends the use of tamoxifen in the reduction of breast cancer risk 
for women at increased risk (NCCN, 2020). 
1.6 Adherence to Management Recommendations 
 There is little data on how previvors are conducting cancer screening and 
management or how closely they are following the NCCN screening guidelines. 
However, in a study by Hesse-Biber and An (2016), researchers looked at surgical 
decision-making among BRCA-positive individuals. The main factors that went into 
surgical decision-making included age, parental status, gender of the children, level of 
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psychological distress from the BRCA result, perceived family support, experienced 
medical uncertainty, and the level of guilt they felt about the possibility of their children 
inheriting the mutation. Interestingly, women who experienced more distress related to 
their BRCA result, those who felt they lacked support from their family, and those who 
perceived more medical uncertainty were more likely to choose surveillance rather than 
surgery (Hesse-Biber & An, 2016). While the study looked at factors influencing their 
management choices, they did not look into how closely surveillance was being followed. 
 Another study, by Hoskins, Roy, and Greene (2012), analyzed patients’ risk 
perception of their BRCA1 or BRCA2 mutation. In their study of 60 participants, 17 had 
already undergone a risk-reducing mastectomy and eight had an oophorectomy. An 
additional 34 participants were either considering or concretely planning a risk-reducing 
mastectomy and 45 were either considering or concretely planning a risk-reducing 
oophorectomy. The authors concluded that many previvors may initially choose to 
manage with increased surveillance before electing to proceed with a risk-reducing 
surgery (Hoskins et al., 2012). Again, this study did not explore what screening these 
participants were doing in place of risk-reducing surgery, suggesting that further research 
in this area is needed. 
1.7 Psychosocial Needs of Previvors 
 Individuals with a predisposition to cancer have unique needs compared to the 
average population. In a study by Dean and Davidson (2018), it was found that these 
individuals may have increased levels of uncertainty compared to those at average risk 
for cancer. In fact, researchers found that previvors experience high levels of uncertainty, 
and increased uncertainty can result in “emotional distress, anxiety, depression, loss of 
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control, and poor decision making and quality of life” (p. 122). In order to manage this 
uncertainty, previvors make decisions based on their perceived risk and available 
information, so it is imperative that these individuals are receiving accurate information 
and support (Dean & Davidson, 2018). 
 Furthermore, Mahon (2014) found that, although some online organizations and 
support groups are available, many of these individuals feel isolated, as if no one else 
understands what they are going through. They may feel as if they are being labeled or 
feel “different from those who do not carry a mutation” (Mahon, 2014, p. 22). Many 
times, support organizations help patients advocate for themselves, an important task as 
they pursue surveillance and management. Previvors have described their experience 
with their healthcare providers as overwhelming and exhausting because they have been 
tasked with teaching their providers about their risk and management instead of receiving 
the empathy and psychosocial support they need (Dean & Davidson, 2018).  
These individuals are even faced with opposition to their decision to select risk-
reducing surgery to reduce cancer risk, with the opposing individuals claiming that 
prophylactic surgery is too extreme. And even if supported in their decision to pursue 
prophylactic surgery, these individuals face unique challenges as a result of their surgery. 
Some women, after a risk-reducing mastectomy, have self-image difficulties and lack of 
security in their identity (Mahon, 2014). After a risk-reducing salpingo-oophorectomy, 
women may experience altered self-image, increased depression, increased fatigue, sleep 
deprivation, and sexual dysfunction that can change her desire for intimacy and 
ultimately affect personal relationships (Alexandre et al., 2017).  
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 Although much of a previvor’s uncertainty may arise from the potential to 
develop cancer, previvors are also concerned about the impact their risk has on other 
family members. In a study assessing perspectives of young adults at risk to have a 
BRCA mutation, many participants emphasized the need for information about 
reproductive issues and family planning (Young et al., 2019). Furthermore, in a study by 
Dean and Rauscher (2017), it was observed that many women who are previvors use two 
types of decision-making styles when thinking about family planning: logical and 
emotional. Logical decision-making involved planning timing for undergoing risk-
reducing surgeries and processing the pressure from healthcare providers to receive 
prophylactic care. Emotional decision-making involved processing her biological time 
clock, her hopes for the future, guilt associated with children possibly inheriting the 
mutation, and consideration of pre-implantation genetic diagnosis (Dean & Rauscher, 
2017). For example, a woman must weigh the option of breastfeeding her child or 
reducing her cancer risk with prophylactic mastectomy. In addition, previvors may be 
worried about the risk to their children and when to communicate that risk (Mahon, 
2014).  
1.8 Utility of a Specialized Management Clinic 
 These unique needs of previvors and high-risk breast cancer patients support the 
necessity of a specialty clinic for previvor management. As described above, 
management for previvors and high-risk breast cancer patients is complex and variable, 
thus it is imperative that individuals are managed by healthcare professionals who are 
knowledgeable about the personalized care required. Studies have shown that obstetrics 
and gynecology providers (OB/GYN) and family practice providers are not able to give 
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previvors optimal care, primarily due to a lack of confidence regarding the management 
recommendations (Dekanek et al., 2019). In fact, in a study of 86 OB/GYN and family 
practice physicians, only 44% of participants felt somewhat confident in discussing 
BRCA management guidelines, and none of the participants indicated that they felt 
completely confident (Dekanek et al., 2019).  
 Other studies have looked at patients’ perceived barriers to getting appropriate 
cancer management. These studies have found that scheduling difficulties are a factor 
preventing proper adherence to management (Goh & Spigelman, 2020; Young et al., 
2019). In addition, confusion surrounding insurance coverage for screening has also been 
found to be a barrier to accessing these services (Dean et al., 2017). Previvors are in need 
of healthcare providers who are not only knowledgeable of the management guidelines, 
but also how to follow through with scheduling and the logistics of following those 
guidelines. 
 Although the services included in a previvor clinic will likely vary between 
clinics, several needs among previvors remain the same. First, because scheduling 
screenings and appointments is a frequent challenge among previvors, a primary role of 
this clinic should be to establish a clear appointment plan for patients. A study by Young 
et al. (2019) of the information needs of previvors found that previvors wanted genetics 
providers to make referrals to other specialists, such as psychologists, surgeons, or other 
specialists. Generally, genetic counselors make the initial recommendations for the 
patient, but rely on the referring provider to make the necessary referrals, potentially 
causing interruptions in the patient’s transition of care. This is largely due to the scope of 
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practice defined by the National Society of Genetic Counselors, which states that genetic 
counselors have the authority to: 
 “Identify, order, and coordinate genetic laboratory tests and other diagnostic 
studies as appropriate for the genetic assessment; integrate genetic laboratory test 
results and other diagnostic studies with personal and family medical history to 
assess and communicate risk factors for genetic/medical conditions and diseases; 
and identify and utilize community resources that provide medical, educational, 
financial, and psychosocial support and advocacy” (National Society of Genetic 
Counselors, 2021).  
Because under the society’s scope of practice genetic counselors are unable to refer to 
outside physicians, this responsibility is placed on either the referring provider or the 
patient to get connected with these medical specialists. 
 One potential model for a previvor clinic has been created by the Stefanie 
Spielman Comprehensive Breast Center in Columbus, Ohio (Senter & Hatfield, 2016). 
This clinic has high-risk breast cancer patients meet with a cancer genetic counselor first 
to take a family history and make genetic testing recommendations if warranted. 
Following the genetic consultation, the patient meets with a nurse practitioner specialized 
in breast health or a breast, surgical, or medical oncologist who assists in making 
management recommendations. Many patients receive high-risk breast cancer screening 
including mammograms, breast MRIs, and clinical evaluation. The clinic model staggers 
these appointments by six months and alternates visits between the physician and the 
nurse practitioner. An updated family history is taken at each visit and the cancer genetic 
counselor may return to see the patient to discuss additional recommendations. Genetic 
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counselors also serve as a resource for questions regarding genetic testing for family 
members or other genetics-related considerations. (Senter & Hatfield, 2016). This model 
addresses the complications of scheduling follow-up appointments for recommended 
management.  
Although many genetic counselors may be unable to serve as full-time staff of a 
previvor clinic, they play an important role in the care of previvors and should be closely 
integrated with a specialty clinic. The exact role of the genetic counselor would likely 
depend on the overall clinic setup as well as the needs of the individual patient. For 
example, a genetic counseling consult may be requested when a patient is considering 
family planning decisions, when family history has changed significantly, or when 
updates to genetic testing have been made. The primary medical staff for a previvor clinic 
would likely consist of a nurse practitioner and/or physician. The nurse practitioner 
and/or physician can provide initial screening services and make referrals to necessary 
specialists including, but not limited to, oncology, plastic surgery, nutritional services, 
psychological services, and reproductive endocrinology. The establishment of a 
specialized previvor clinic would allow for unhindered access to resources and support in 
cancer prevention and management, which has potential to improve outcomes for these 
individuals (Senter & Hatfield, 2016).  
1.9 Rationale of Study 
Although there is research into the unique needs of previvors and individuals at an 
increased risk for cancer, there is little information about previvors’ opinions on the 
establishment of a management clinic in general, and nothing specific for the state of 
South Carolina. The goal of this study is to determine if patients in Columbia, South 
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Carolina would benefit from the establishment of a specialized management clinic, and if 
so, what services these individuals need. It is our belief that this study will bring no harm 
to the participant but will provide valuable insight into how to best care for this patient 
population. We will also pull from experiences from a currently established clinic in 
South Carolina to gather opinions on an already available service. 
1.10 Objectives 
1. Determine if there is desire and/or need for a previvor clinic in Columbia, South 
Carolina 
2. Determine the utility and efficacy of the Genetics Management Clinic and High-
Risk Breast Lifetime Clinic in Greenville, South Carolina 
3. Determine what services should be incorporated into such a clinic and how often 
patients would require these services 
4. Assess whether patients who had access to a previvor clinic were better able to 
adhere to management recommendations compared to those who did not have 
access 
1.11 Hypothesis 
It is hypothesized that without clear direction and guidance from knowledgeable 
health professionals, many previvors may struggle to adhere to NCCN management 
guidelines. Without proper care, previvors are at risk for worsened health outcomes, so it 
is expected that this study may improve overall patient satisfaction and care. 
Furthermore, it is anticipated that patients within the Columbia, South Carolina area will 
have strong interest for the establishment of a local previvor clinic and that patients who 
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have attended the specialty clinic in Greenville will experience high patient satisfaction 
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2.1 Abstract 
 Approximately 5-10% of cancers are thought to be hereditary, caused by 
pathogenic variants in genes associated with inherited cancer syndromes. Previvors, 
individuals who have a higher predisposition to cancer due to genetic or other risk 
factors, have specific healthcare and psychological needs that may be better served by a 
specialized management clinic. This study compared the experiences of previvors who 
had access to a specialized management clinic with those who did not, in order to better 
understand the unique needs of previvors. This study utilized a mixed methods design 
including an online survey (N=26) and semi-structured phone interview (N=6). Overall, 
previvors with access to a specialized management expressed less stress (N=5), less delay 
in care (N=2), access to a simplified clinical process (N=5), and the information needed 
to make informed decisions regarding their medical care (N=8). Previvors who did not 
have access to a specialty clinic described challenges with finding information about their 
risk, receiving care from general practitioners, and having questions unanswered by 
healthcare providers, further supporting previous literature that investigated the nuanced 
care required by previvors. Previvors without access to a management clinic desired a 
team of specialists familiar with genetics, a forum to ask questions, and a clinic that 
would ensure their care meets the current recommendations. This study demonstrates the 
need for specialized management clinics designed with previvors’ needs in mind in order 
to provide these patients with the most appropriate care. 
2.2 Introduction 
Approximately 5-10% of cancers are thought to be hereditary. Hereditary cancer 
is caused by mutations in genes associated with hereditary cancer syndromes, and a 
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pathogenic mutation results in a significantly increased risk for cancer development 
compared to that of the average population (Senter & Hatfield, 2016). Mutations that 
cause hereditary cancer syndromes are identified through the use of genetic testing, 
specifically testing that targets oncogenes and tumor suppressor genes, genes associated 
with regulation of cell growth and hereditary cancer (Dekanek et al., 2019). Once a 
pathogenic mutation has been identified, it is recommended that the patient pursue 
management specific to their cancer risks, often as directed by the guidelines established 
by the National Comprehensive Cancer Network (NCCN), a society recognized in the 
medical community to be an authority on cancer care (NCCN, 2020). 
There are a large number of genes associated with hereditary cancer. This study 
encompassed individuals with mutations in ATM, BRCA1, BRCA2, CDH1, CHEK2, 
PALB2, PTEN, and TP53. While these genes are mainly associated with breast cancer, 
mutations in them also carry other cancer risks. In addition, these genes have specific 
management recommendations established by NCCN that aid in patient care (NCCN, 
2020). 
Genetic testing for hereditary cancer syndromes is recommended for individuals 
who meet certain criteria as determined by NCCN. One example of this criteria is the 
Testing Criteria for High-Penetrance Breast and/or Ovarian Cancer Susceptibility Genes, 
determined by NCCN (NCCN, 2020). If criteria are met, and no familial mutation has 
been identified, providers should consider comprehensive testing for the patient with a 
multi-gene panel (NCCN, 2020). NCCN (2020) recommends genetic testing for 
hereditary breast and ovarian cancer for patients with certain cancer diagnoses or if a 
family history meets certain criteria. 
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By pursuing testing for a known familial variant or because of a family history of 
cancer, individuals are learning of their previvor status. The term previvor was initially 
coined by the advocacy group, Facing Our Risk of Cancer Empowered (FORCE), and is 
used to describe individuals “who have a much greater predisposition to cancer than 
individuals in the general population but who have not yet developed the disease” 
(Carvalho et al., 2019, p. 1). This greater susceptibility may be due to the presence of a 
pathogenic mutation in a hereditary cancer gene or other factors including family history 
(Getachew-Smith et al., 2019). It has been recognized that individuals falling within the 
previvor category have “specific psychosocial and healthcare needs…to help them decide 
how to manage this substantial risk” (Mahon, 2014, p. 21). 
Individuals with mutations in hereditary cancer genes have specific management 
recommendations established by the National Comprehensive Cancer Network, but 
recommendations differ slightly from gene to gene. Individuals who fall into the previvor 
category based on family history or other factors can be identified using verified risk 
models, such as Tyrer-Cuzick, Gail, BRCAPRO, Claus, and BOADICEA. Women with a 
lifetime risk of breast cancer greater than or equal to 20% as determined by these models 
are recommended to have additional screening similar to that recommended for 
individuals with a genetic mutation (Monticciolo et al., 2018). Recommendations include 
breast awareness, clinical breast exams every six to twelve months, annual breast MRI 
beginning at age 25, annual mammogram beginning at age 30, and incorporation of risk-
reducing strategies, such as the use of tamoxifen as a form of chemoprevention (NCCN, 
2020). Because cancer risks vary from gene to gene, it is important to know the patient’s 
carrier status when determining a management plan.  
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 There is little data on how previvors are conducting cancer screening and 
management or how closely they are following the NCCN screening guidelines. 
However, in a study by Hesse-Biber and An (2016), researchers looked at surgical 
decision-making among BRCA-positive individuals. The main factors that went into 
surgical decision-making included age, parental status, gender of the children, level of 
psychological distress from the BRCA result, perceived family support, experienced 
medical uncertainty, and the level of guilt they felt about passing the mutation to their 
children. Women who experienced more distress related to their BRCA result, those who 
felt they lacked support from their family, and those who perceived more medical 
uncertainty were more likely to choose surveillance rather than surgery (Hesse-Biber & 
An, 2016). Another study, by Hoskins, Roy, and Greene (2012), analyzed patients’ risk 
perception of their BRCA1 or BRCA2 mutation. In their study of 60 participants, 17 had 
already undergone a prophylactic mastectomy and eight had completed an oophorectomy. 
An additional 34 participants were either considering or concretely planning a risk-
reducing mastectomy and 45 were either considering or concretely planning a 
prophylactic oophorectomy. The authors concluded that many previvors may initially 
choose to manage with increased surveillance before electing to proceed with 
prophylactic surgery (Hoskins et al., 2012). Neither study explored previvors’ adherence 
to management recommendations if proceeding with screening surveillance, suggesting 
that further research in this area is needed. 
 Individuals with a predisposition to cancer have unique needs compared to the 
average population. In a study by Dean and Davidson (2018), it was found that these 
individuals may have increased levels of uncertainty compared to those at average risk 
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for cancer. In fact, researchers found that previvors experience high levels of uncertainty, 
and increased uncertainty can result in “emotional distress, anxiety, depression, loss of 
control, and poor decision making and quality of life” (p. 122). In order to manage this 
uncertainty, previvors make decisions based on their perceived risk and available 
information, so it is imperative that these individuals are receiving accurate information 
and support (Dean & Davidson, 2018). Furthermore, Mahon (2014) found that, although 
some online organizations and support groups are available, many of these individuals 
feel isolated, labeled, or feel different from others without a mutation.  
Previvors have described their experience with their healthcare providers as 
overwhelming and exhausting because they have been tasked with teaching their 
providers about their risk and management instead of receiving the empathy and 
psychosocial support they need (Dean & Davidson, 2018). These individuals are even 
faced with opposition to their decision to select risk-reducing surgery to reduce cancer 
risk, by claims that prophylactic surgery is too extreme. And even if supported in their 
decision to pursue prophylactic surgery, these individuals face unique challenges as a 
result of their surgery. Some women, after a risk-reducing mastectomy, have self-image 
difficulties and lack of security in their identity (Mahon, 2014). After a risk-reducing 
salpingo-oophorectomy, women may experience altered self-image, increased depression, 
increased fatigue, sleep deprivation, and sexual dysfunction that can change her desire for 
intimacy and ultimately affect personal relationships (Alexandre et al., 2017).  
 Although much of a previvor’s uncertainty may arise from the potential to 
develop cancer, previvors are also concerned about the impact their risk has on other 
family members. In a study assessing perspectives of young adults at risk to have a 
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BRCA mutation, many participants emphasized the need for information about 
reproductive issues and family planning (Young et al., 2019). Individuals who carry a 
genetic mutation are at risk of their children inheriting this mutation and also have to 
weigh the option of breastfeeding their child or reducing their cancer risk with risk-
reducing mastectomy. In addition, previvors may be worried about the risk to their 
children and when to communicate about that risk (Mahon, 2014).  
 These unique needs of previvors and high-risk breast cancer patients support the 
necessity of a specialty clinic for previvor management. As described above, 
management for previvors and high-risk breast cancer patients is complex and variable, 
thus it is imperative that individuals are managed by healthcare professionals who are 
knowledgeable about the personalized care required. Studies have shown that obstetrics 
and gynecology (OB/GYN) providers and family practice providers are not able to give 
previvors optimal care, primarily due to a lack of confidence regarding the management 
recommendations (Dekanek et al., 2019). In fact, in a study of 86 OB/GYN and family 
practice physicians, only 44% of participants felt somewhat confident in discussing 
BRCA management guidelines, and none of the participants indicated that they felt 
completely confident (Dekanek et al., 2019).  
 Other studies have looked at patients’ perceived barriers to getting appropriate 
cancer management. These studies have found that scheduling difficulties are a factor 
preventing proper adherence to management (Goh & Spigelman, 2020; Young et al., 
2019). In addition, confusion surrounding insurance coverage for screening has been 
found to be a barrier to accessing these services (Dean et al., 2017). Previvors are in need 
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of healthcare providers who are not only knowledgeable of what the guidelines are, but 
also how to follow through with scheduling and logistics of following those guidelines. 
 Although the services included in a previvor clinic will likely vary from clinic to 
clinic, several needs among previvors remain the same. First, because scheduling 
screenings and appointments is a frequent challenge among previvors, a primary role of 
this clinic should be to establish a clear appointment plan for patients. A study by Young 
et al. (2019) of the information needs of previvors found that previvors wanted genetics 
providers to make referrals to other specialists, such as psychologists, surgeons, or other 
specialists. Generally, genetic counselors make the initial recommendations for the 
patient, but rely on the referring provider to make the necessary referrals, potentially 
causing interruptions in the patient’s transition of care. 
 One potential model for a previvor clinic has been created by the Stefanie 
Spielman Comprehensive Breast Center in Columbus, Ohio (Senter & Hatfield, 2016). 
This clinic has high-risk breast cancer patients meet with a cancer genetic counselor first 
to take a family history and make any genetic testing recommendations if warranted. 
Following the genetic consultation, the patient meets with a nurse practitioner specialized 
in breast health or a breast, surgical, or medical oncologist who assist in making 
management recommendations. Many patients receive high-risk breast cancer screening 
including mammograms, breast MRIs, and clinical evaluation. The clinic model staggers 
these appointments by six months and alternates visits between the physician and the 
nurse practitioner. An updated family history is taken at each visit and the cancer genetic 
counselor may return to see the patient to discuss additional recommendations. Genetic 
counselors also serve as a resource for questions regarding genetic testing for family 
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members or other genetics-related considerations (Senter & Hatfield, 2016). The model 
addresses the issues of scheduling follow-up appointments for management. Clinic 
organization will vary, as will the role of the genetic counselor’s involvement, but 
patients need access to a provider who can refer to specialists and establish support 
resources, and a similar model to the one described above would be of great benefit to the 
patients of Columbia, South Carolina. 
 The goal of this study was to determine if there was a desire and/or need for a 
previvor clinic in Columbia, South Carolina and to determine the utility and efficacy of 
the existing clinics in Greenville, South Carolina—the Genetics Management Clinic and 
High-Risk Breast Lifetime Clinic. In addition, researchers sought to determine what 
services ought to be incorporated into such a clinic and how often patients would require 
these services. Lastly, by comparing experiences of individuals at both hospitals, 
researchers hoped to assess whether patients who had access to a previvor clinic were 
better able to adhere to management recommendations compared to those who did not 
have access. It was hypothesized that, without clear direction and guidance from 
knowledgeable health professionals, many previvors may struggle to adhere to NCCN 
management guidelines. Without proper care, previvors are at risk for worsened health 
outcomes, so it is expected that this study may improve overall patient satisfaction and 
care. Furthermore, it was anticipated that patients within the Columbia, South Carolina 
area would have strong interest for the establishment of a local previvor clinic and that 
patients who have attended the specialty clinic in Greenville experienced high patient 




2.3.1 IRB Approval 
 This study was approved by the Institutional Review Board, Office of Research 
Compliance, of the University of South Carolina, Columbia, SC in July 2020. 
2.3.2 Participants 
Participants included in this study were patients who had a genetic counseling 
appointment at Prisma Health-Midlands in Columbia, South Carolina or an appointment 
at the Genetics Management Clinic or High-Risk Breast Lifetime Clinic at Prisma Health 
Upstate in Greenville, South Carolina. To be included in the study, patients were required 
to meet the following inclusion criteria: Mutation-positive in a hereditary cancer gene 
that predisposes to breast cancer and has NCCN management recommendations, 
including: ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, TP53, or have a 
Tyrer-Cuzick or other risk model score of 20% or greater, requiring additional 
management as dictated by the NCCN Genetic/Familial High-Risk Assessment: Breast, 
Ovarian and Pancreatic guidelines; and never had a diagnosis of cancer (NCCN, 2020). 
Prisma Health-Midlands patients who are mutation-positive were recruited 
retroactively through the clinic’s database and prospectively as encountered by the 
Prisma Health-Midlands genetic counselors. Prisma Health-Midlands patients who are 
considered high-risk given their Tyrer-Cuzick score were informed of the study 
prospectively by their genetic counselor. Prisma Health-Upstate patients who have visited 
the Genetics Management Clinic or High-Risk Breast Lifetime Clinic and met the 
inclusion criteria were identified through the clinic’s records and sent a recruitment letter 
inviting them to participate in the study.   
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2.3.3 Online Survey 
 Participants were mailed a letter inviting them to complete an online survey 
through QualtricsXM software. Invitation letters were mailed out to patients of the 
Genetics Management Clinic and High-Risk Breast Lifetime Clinic in August 2020. 
Additionally, Prisma Health-Midlands patients who received genetic counseling in the 
past and were mutation-positive also were sent an invitation letter at this time. Beginning 
in August 2020, Prisma Health-Midlands patients who received negative genetic testing 
but were identified to be high risk for breast cancer were given a letter by their genetic 
counselor, inviting them to participate in the study. Included in the recruitment letter was 
a link to the participant’s clinic-specific survey (Appendix A-C). The survey remained 
open until November 15, 2020. At the beginning of the survey, participants were asked to 
provide informed consent by selecting the “I consent” option. Data collection was kept 
anonymous to protect the privacy of the participants.  
 Surveys were unique to the clinic the participants were involved with and 
included a mixture of questions addressing patient demographic information, genetic 
status, clinic satisfaction, and further suggestions for clinic development and 
improvement (Appendix D-F). The final question of all three surveys invited participants 
to list their phone number if interested in participating in a semi-structured phone 
interview. By providing their phone number, participants consented to being contacted by 
the principal investigator for this purpose. 
2.3.4 Semi-Structured Interviews 
 Participants who indicated on the survey their willingness to partake in an 
additional interview were called to complete a semi-structured phone interview regarding 
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their experiences at their respective clinic (i.e., Prisma Health-Midlands Genetic 
Counseling, Genetics Management Clinic, or High-Risk Breast Lifetime Clinic). Prior to 
beginning the interview, participants were asked to give verbal consent to participate in 
the interview and have their responses recorded. Surveys were transcribed by hand, 
labeled numerically by the order in which they were completed, and secured on a 
password-protected computer. 
2.3.5 Data Analysis 
 All data remained deidentified to protect the privacy of the participants. Survey 
responses to multiple choice questions and ranking activities were analyzed and 
frequencies were recorded for analysis. Free response questions and qualitative 
interviews were analyzed for themes using a grounded theory approach, and shared 
themes were drawn from both the surveys and interviews. This analysis was completed 
by two independent researchers (M.T. and W.D.), and categories were discussed until 
three common themes were agreed upon. 
2.4 Results 
2.4.1 Participation and Demographics 
 A total of 28 surveys were started, and 26 were completed across the three clinics. 
Seven surveys were completed by Prisma Health-Midlands patients, ten by Genetics 
Management Clinic patients, and nine by High-Risk Breast Lifetime Clinic patients. Six 
semi-structured phone interviews were completed—four by Prisma Health-Midlands 
patients and two by Genetics Management Clinic patients. An additional eight 
participants indicated on their survey that they would be willing to complete a semi-
structured phone interview but were unable to be contacted to arrange the interviews. 
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Table 2.1 Demographic Characteristics of Participants 
Characteristic N (Percentage) 
Clinic 
Prisma Health-Midlands                                               7 (26.9%) 
High-Risk Breast Lifetime Clinic 10 (38.5%) 
Genetics Management Clinic 9 (34.6%) 
Age (Obtained for Prisma Health-Midlands Only) 
     18-25 1 (14.3%) 
     26-30 1 (14.3%) 
     31-40 1 (14.3%) 
     41-50 0 (0%) 
     51-60 2 (28.6%) 
     61-70 1 (14.3%) 
     Over 70 1 (14.3%) 
Genetic Status 
     Positive 16 (61.5%) 
     Negative/High-Risk 10 (38.5 %) 
Gender* 
     Female 26 (100%) 
     Male 0 (0%) 
*Both men and women were eligible for the study, however, all participants reported 
female gender identity. 
2.4.2 Prisma Health-Midlands 
 A total of nine surveys were started, and seven surveys were completed. Of the 
seven completed surveys, six participants indicated they had a mutation in a hereditary 
cancer gene, while the remaining participant had a high lifetime risk for breast cancer 
based on her family history. Figure 2.1 shows the risk status of Prisma Health-Midlands 
participants, including genes in which participants had a pathogenic variant and those 
who tested negative and are high risk based on other factors. 
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Figure 2.1 Prisma Health-Midlands Risk Status 
One participant had a history of cancer, and as a result, the survey was ended after 
answering that she had a cancer diagnosis. Therefore, the total number of complete, 
eligible responses for the Prisma Health-Midlands clinic was six surveys. 
 Participants were asked to rate their attitudes regarding their risk perception and 
care they currently receive related to their cancer predisposition. These attitudes are 
summarized in Table 2.2. 
Table 2.2 Patient Attitudes Regarding Cancer Risk and Care 
Patient Attitudes 
 N (Frequency) 
I feel I have adequate knowledge about my cancer risk and am able to manage my 
personal healthcare to meet the recommendations. 
Strongly agree 1 (16.7%) 
Somewhat agree 3 (50%) 
Neither agree nor disagree 2 (33.3%) 
Somewhat disagree 0 (0%) 
Strongly disagree 0 (0%) 
I feel that my healthcare providers (primary care physician, obstetrician, gynecologist, 
etc.) have expert knowledge about the cancer screenings recommended for me. 
Strongly agree 0 (0%) 
Somewhat agree 2 (33.3%) 











Prisma Health-Midlands Risk Status
BRCA1 BRCA2 CHEK2 PALB2 Negative High-Risk
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Somewhat disagree 1 (16.7%) 
Strongly disagree 1 (16.7%) 
I have difficulty getting insurance coverage for the recommended cancer screenings. 
Strongly agree 1 (16.7%) 
Somewhat agree 0 (0%) 
Neither agree nor disagree 3 (50%) 
Somewhat disagree 1 (16.7%) 
Strongly disagree 1 (16.7%) 
Some institutions have set up clinics designed to assist individuals who carry a positive 
mutation in a hereditary cancer gene or who are at a higher risk for developing breast 
cancer get the recommended screenings and management. How interested would you 
be in attending this clinic if it were created at Prisma Health-Midlands? 
Very interested 6 (100%) 
Somewhat interested 0 (0%) 
Neutral 0 (0%) 
Likely not interested 0 (0%) 
Not at all interested 0 (0%) 
How often would you want to attend this type of clinic? (If other, please specify in the 
provided blank.) 
Only once 1 (16.7%) 
Every 5 years 0 (0%) 
Every 2 years 0 (0%) 
Every year 1 (16.7%) 
Every 6 months 2 (33.3%) 
Other— “As often as recommended” 1 (16.7%) 
Other— “Every 3 months” 1 (16.7%) 
 
 The majority of participants reported feeling very confident or somewhat 
confident that they had adequate knowledge of their cancer risks and had the ability to 
manage their healthcare accordingly (N=4, 66.7%). However, when asked the degree to 
which they agree that their healthcare providers had expert knowledge of their cancer risk 
and the recommended screenings, no participants strongly agreed. One-third (33.3%, 
N=2) somewhat felt that their providers had expert knowledge regarding their risks and 
management, and one-third (33.3%, N=2) of participants did not feel they had this 
knowledge. 
 32 
 All six participants (100%) indicated that they were very interested in attending a 
specialized management clinic if one were developed at Prisma Health-Midlands. 
Participants were then given a list of possible services and asked to rank these services in 
order of most important to least important for incorporation into a specialized 
management clinic. Services were ranked by each participant and weighted frequencies 
were calculated for each category based on participant responses (Appendix G). The 
results of this ranking question are summarized in Figure 2.2. 
 
Figure 2.2 Ranked Preferences of Services—Prisma Health-Midlands 
 
The majority of participants ranked access to cancer screenings (i.e., mammogram, breast 

































Ranked Preferences of Services -
Prisma Health-Midlands
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2.4.3 Genetics Management Clinic  
 A total of ten surveys were completed by patients of the Genetics Management 
Clinic; however, only four of the participants met all of the inclusion criteria for the 
study. Due to the limited number of responses, answers from participants who completed 
the survey but had a personal history of cancer were still included.  
 Participants identified as having pathogenic variants in three hereditary cancer 
genes: BRCA1, BRCA2, and PALB2, with the majority of participants (N=5, 50%) 
carrying a BRCA2 variant. Figure 2.3 shows the breakdown of genetic mutation status by 
gene.  
 
Figure 2.3 Genetics Management Clinic Genetic Mutation Status 
 After learning of their genetic status, the majority of participants (N=8, 80%) 
have attended the Genetics Management Clinic for longer than 18 months. On average, 
most participants attended the clinic once per year and felt that this interval between 
visits was appropriate (N=9, 90%). When asked to rate their satisfaction with the clinic on 











(N=9) rated their satisfaction with the clinic a 10, very satisfied. Additionally, all ten 
participants indicated that they would recommend the GMC to others (100%).  
2.4.4 High-Risk Breast Lifetime Clinic 
 A total of nine surveys were completed by participants of the High-Risk Breast 
Lifetime Clinic. 88.9% of participants (N=8) have attended the High-Risk Breast 
Lifetime Clinic for at least 12 months. Four participants indicated that they visit the 
High-Risk Breast Lifetime Clinic semi-annually (50%), three participants attend annually 
(37.5%), and one participant no longer attends the clinic (12.5%). Overall, participants 
expressed high satisfaction with the care they received at the High-Risk Breast Lifetime 
Clinic as seen in Table 2.3, with all participants ranking their satisfaction greater than or 
equal to seven on a number scale identifying satisfaction, and the majority (55.5%, N=5) 
ranking satisfaction greater than or equal to nine. Two-thirds (66.7%, N=6) expressed 
that breast cancer screenings had gotten easier since attending the High-Risk Breast 
Lifetime Clinic.  
Table 2.3 High-Risk Breast Lifetime Clinic Patient Satisfaction and Clinic Utility 
High-Risk Breast Lifetime Clinic Patient Satisfaction  
and Clinic Utility 
 N (Frequency) 
On a scale from 0-10, with 0 being not at all satisfied and 10 being very 
satisfied, how satisfied are you with the services provided by the High-
Risk Breast Lifetime Clinic? 
0- not at all satisfied 0 (0%) 
1 0 (0%) 
2 0 (0%) 
3 0 (0%) 
4 0 (0%) 
5 0 (0%) 
6 0 (0%) 
7 2 (22.2%) 
8 2 (22.2%) 
9 2 (22.2%) 
10- very satisfied 3 (33.3%) 
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Has getting breast cancer screening (i.e., mammograms and breast MRIs) 
gotten easier since attending this clinic? 
Yes 6 (66.7%) 
No 2 (22.2% 
Not sure 1 (11.1%) 
 
2.4.5 Experiences with Genetic Counseling 
 All participants were able to meet with a genetic counselor either prior to or 
following genetic testing. Participants expressed high levels of satisfaction with their 
genetic counseling experience, especially in terms of level of thoroughness and education 
they received regarding their cancer risk. Participants appreciated the expert genetic 
knowledge of genetic counselors coupled with their attention to psychosocial concerns of 
the patient and their relatives. Participants described the process of meeting with a 
genetic counselor to discuss genetic test results, associated risks, and options for future 
care. One participant compared her experience seeing a genetic counselor at Prisma 
Health-Midlands to her sister’s experience at her doctor’s office:  
Well, I was so pleased with the whole experience with the genetic counseling… 
And when I compare my experience to my sister who just had a blood test at her 
OB/GYN and just sent a letter in the mail, she really had no counseling. She filled 
out a family history, but nobody questioned or interviewed her or anything. 
Totally different experience. And she was so jealous when I told her my 
experience and what I went through and how supportive everybody was. (Prisma 
Health-Midlands Participant 7) 
As described by Prisma Health-Midlands Participant 7 and several others, benefits of 
genetic counseling included psychosocial support, thorough education regarding cancer 
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risks, and discussion of options to reduce cancer risk (Prisma Health-Midlands 
Participant 7, Genetics Management Clinic Participant 4 & 5). 
2.4.6 Experiences of Participants Without a Specialized Clinic 
 Without access to a specialized management clinic, participants rely on online 
support groups, current medical providers, and self-advocacy to get care related to their 
cancer predisposition. After learning of her CHEK2 mutation, Prisma Health-Midlands 
Participant 1 relied on a Facebook group for CHEK2 mutation carriers to keep her up to 
date. Members of the Facebook group willingly shared their experiences and research on 
CHEK2 variants, but this led to additional questions about associated cancer risks and 
management options. Prisma Health-Midlands Participant 1 described the dynamic of this 
group as a “big question and a big waiting game,” when expressing the confusion that can 
surround online support groups. Despite some confusion regarding cancer risks, Prisma 
Health-Midlands Participant 1 pointed out that a major benefit of the online support 
group was the allied search for information. She described that the members of the group 
actively search out research regarding CHEK2 and willingly share it with the group, 
although she recognized that information is somewhat limited. 
Other participants relied on support from their family members who also carry the 
same variant. Prisma Health-Midlands Participant 4 described talking with her mother 
about their risks for breast cancer: She recalled talking with her mother about the 
different options for risk-reduction but concluded that they would address cancer or 
management if it came to fruition.  
 Previvors without a specialized management clinic relied on the experience of 
their current medical provider (primary care physician, OB/GYN, etc.) for care related to 
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their increased risk for breast and other cancers. Some participants expressed high levels 
of satisfaction with their current provider’s knowledge regarding their cancer 
predisposition, while others felt that they had to educate their providers about their 
increased risk and recommended risk-reduction options. Prisma Health-Midlands 
Participant 1 described her visits with her nurse practitioner after learning of her positive 
CHEK2 variant and explained that her nurse practitioner had been helpful in arranging 
the necessary screenings. Together, they looked at her genetic testing results and 
recommendations for management and came up with a plan of action, including 
scheduling a mammogram and breast MRI. Prisma Health-Midlands Participant 1 also 
planned to discuss scheduling a colonoscopy in the near future and believed that her 
nurse practitioner would be able to help facilitate that referral. 
Although Prisma Health-Midlands Participant 1 felt that her provider was well-
equipped to care for her, not all participants felt the same regarding their providers. 
Prisma Health-Midlands Participant 3 found that some of her providers did not fully 
understand her cancer predisposition or the recommendations for screenings or risk-
reducing care: 
It’s hard to like to tell a doctor like, “hey, I need this done or this done,” you 
know, like when… it’s hard to speak up and say that when they know so much 
more about medical things than you do. (Prisma Health-Midlands Participant 3) 
Prisma Health-Midlands Participant 7 described a similar situation in which a provider 
could not comprehend her desire to reduce her breast cancer risk in any way possible:  
Because after watching family members go through this, I have even asked my 
doctor—before we even talked about the genetic counseling—I asked her about 
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the possibility of having my breasts removed. And she looked at me like, “What?” 
And I’m like, “Well, you know, that would just kind of eliminate that…” I’m 
open to anything. Whatever I can do to not have to go through what I’ve watched 
other family members go through. (Prisma Health-Midlands Participant 7) 
Like Prisma Health-Midlands Participants 3 and 7 described, previvors without a 
specialized clinic felt they needed to self-advocate for their desire to be proactive to 
healthcare providers who did not understand their risk, but previvors also found they had 
to do so with family members who did not understand their desire to reduce cancer risk in 
any way possible. Prisma Health-Midlands Participant 1 described a conversation with 
her husband regarding genetic testing and risk reduction in which he described genetic 
testing as “fearmongering,” but she defended her position on testing and risk-reduction 
because of experiencing the loss of a close friend at age 29 due to breast cancer, claiming 
that she would do anything she could to be prepared. These encounters with people who 
do not understand their predisposition, have sparked participants to do everything in their 
own power to prevent cancer. 
 When asked what features participants would include in an ideal management 
clinic, participants highlighted the need for access to specialists familiar with genetics, a 
provider who will notify of changes to risk or management recommendations, and a place 
to ask questions. Participants desired a specialist familiar with genetics and able to 
provide expert care specific to their risks, whether due to a genetic mutation or family 
history. Prisma Health-Midlands Participant 4 described how the providers at a local 
women’s center performed her breast ultrasound and were familiar with breast health but 
did not have expert knowledge on the genetic aspects of her care. After leaving her visit 
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at the women’s center, she felt that there were still probably things related to her risk that 
she didn’t know about. She emphasized the difference between a women’s center who 
specializes in women’s care and breast cancer screening versus a center that focuses on 
this care and screening within the context of previvorship. Prisma Health-Midlands 
Participant 3 echoed this sentiment, saying that she simply wanted a place where the 
doctors were familiar with the higher risks of previvors. 
 A second priority for a specialized management clinic was the ability to be 
notified of changes to cancer risks or management recommendations. Prisma Health-
Midlands Participant 4 indicated that this would be a priority for her when thinking about 
a specialized clinic and emphasized her desire for a healthcare provider that could follow 
her along and provide updates on changes to care. Similarly, Prisma Health-Midlands 
Participant 1 valued the idea of having a specific provider to keep patients informed, to 
help patients stay informed and on top of their care in addition to providing resources. 
She also emphasized the importance of having new information explained by a medical 
professional in layman’s terms, ensuring their ability to utilize that information. 
 In addition to using the clinic as a way to stay informed, participants also wanted 
the clinic to serve as the place to ask questions and get specific recommendations based 
on their genetic mutation or family history. Prisma Health-Midlands Participant 1 
described the confusion that has come up in her CHEK2 Facebook group regarding 
associated cancers and risks and described that a specialized management clinic with 
specific knowledge regarding care for individuals with a CHEK2 mutation would be 
extremely beneficial in order to get her questions answered. Prisma Health-Midlands 
Participant 4 expressed interest in asking questions about risk-reducing surgeries and 
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other screening options and felt that there was probably information about these options 
that she was unfamiliar with. Similarly, Prisma Health-Midlands Participant 7 discussed a 
conversation with her sister about taking tamoxifen and how she was not certain that 
taking it was still recommended. She also had questions regarding the benefits of a breast 
MRI and the logistics of getting one.  
2.4.7 Experiences of Participants with a Specialized Clinic 
 Participants from the Genetics Management Clinic and High-Risk Breast Lifetime 
Clinic expressed that access to a specialized management clinic provided a simplified and 
efficient management process, streamlining their care. Genetics Management Clinic 
Participant 4 described the role of the nurse practitioner who heads the clinic as a 
navigator and facilitator. The nurse practitioner would provide referrals to the necessary 
specialists, assist in scheduling appointments for consults and imaging, and provided 
insight on proper care and management. By navigating the process alongside the patient, 
the nurse practitioner was able to expedite care and ensure the patient received the 
appropriate services, removing the burden from the patient. High-Risk Breast Lifetime 
Clinic Participant 7 echoed this feeling, stating that the High-Risk Breast Lifetime Clinic 
providers had an expert focus on identifying, treating, and curing breast disease, which 
she found particularly helpful. High-Risk Breast Lifetime Clinic Participant 8 expressed 
that the ease of visits and concentration on breast cancer risk-reduction and care were the 
most valuable aspects of the clinic.  
 In addition to providing care in a simplified manner, participants expressed that 
this system also prevented delays to care. Genetics Management Clinic Participant 7 
mentioned that she was able to get a second surgery quicker because of having access to 
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the physicians at the Genetics Management Clinic. Genetics Management Clinic 
Participant 4 discussed how she might have approached clinical care after learning of her 
BRCA1 mutation, and how the clinic’s approach ensured she saw the proper physicians 
quickly. Instead of seeing one doctor at a time and approaching care in a step-wise 
fashion, the clinic made the referrals simultaneously. Having access to a specialized 
management clinic allowed her care to be expedited compared to if she had coordinated 
her care plan own her own. She believed that she would’ve seen all of the recommended 
physicians eventually, but never would have done so at such a high speed if it had not 
been for the Genetics Management Clinic.  
 Study participants emphasized that a major benefit of the Genetics Management 
Clinic and High-Risk Breast Lifetime Clinic is access to healthcare providers who give 
detailed education regarding risk and the necessary information to come to an informed 
decision regarding care and risk-reduction. Genetics Management Clinic Participant 8 
described genetic counseling as the most valuable service of the Genetics Management 
Clinic and how after discussing her mutation in-depth, she felt much better about her plan 
for care. Genetics Management Clinic Participant 5 expressed similar feelings and 
explained how receiving thorough education about her genetic mutation and what it 
meant allowed her to not only be proactive but gave her a sense of control. By receiving 
proper education about their elevated risk for developing cancer, participants were able to 
make educated, well-informed decisions relating to their care plan, whether electing to 
proceed with screening or a risk-reducing surgery. 
 Furthermore, access to the Genetics Management Clinic or High-Risk Breast 
Lifetime Clinic reduced participant stress related to receiving care. Several participants 
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described the sense of relief they experienced after connecting with the clinic. Genetics 
Management Clinic Participant 5 highlighted this feeling when describing how the clinic 
recommended where to go, which providers to see, and facilitating scheduling. By 
leaving this in the hands of the Genetics Management Clinic, she was able to feel more 
relaxed and less overwhelmed by the process. High-Risk Breast Lifetime Clinic 
Participant 5 shared that she found “peace of mind knowing the High-Risk Breast 
Lifetime Clinic is closely monitoring everything.” Numerous participants expressed that 
the process of learning of their increased risk and determining a management plan could 
be overwhelming, but the clinics help make it manageable (Genetics Management Clinic 
Participant 5). Genetics Management Clinic Participant 4 describes the overall impact the 
Genetics Management Clinic had on her, saying: 
I would just say that they're useful. I mean, if it wasn’t for the clinic, could I have 
done all this? Yes, but with them doing it, it was more efficient, it was less 
stressful for me, it was one less thing I had to research. It just made the whole 
process just a little bit easier—a lot easier, not a little, a lot. I only have positive 
things to say. (Genetics Management Clinic Participant 4) 
2.5 Discussion  
2.5.1 Specialized Management Clinic for Psychosocial Support 
Participants who did not have access to a specialized management clinic all 
indicated that they would be interested in attending such a clinic if one were to be 
established in the Midlands region. The study sought to identify current practices and 
resources that these participants utilize, as well as their preferences for the setup of a 
specialized management clinic in the future. Participants currently utilize online support 
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groups as well as family members who also are at increased risk for developing cancer as 
a support resource, relying on these individuals not only for psychological support, but 
also as a source of information regarding risk and risk-reduction.  
Mahon (2014) found that previvors often feel isolated, as if no one else 
understands what they are going through and “different from those who do not carry a 
mutation” (Mahon, 2014, p. 22). Study participants, like the participant that joined a 
Facebook group, expressed similar feelings to that found by Mahon. These findings 
indicate that a psychosocial support aspect to a specialized clinic may also be beneficial. 
Leaning into a support community allowed for not only psychological support, 
but also further information and education regarding cancer risk and current research. 
However, despite the benefits gained from the previvor community, Prisma Health-
Midlands Participant 1 also expressed concerns with the contrasting information shared 
within the group, sharing that that some Facebook users had certain perceptions regarding 
associated cancer risks while others held different perceptions. This experience suggests 
that support groups may be beneficial for encouragement and learning from other 
previvors but may not be the most appropriate place for effective education.  
In terms of psychological health, numerous participants with access to the 
Genetics Management Clinic described how the management clinic helped reduce their 
levels of stress (Genetics Management Clinic Participants 1, 4, & 5, High-Risk Breast 
Lifetime Clinic Participant 5). Genetics Management Clinic Participant 5 described how 
the process “can be overwhelming, and they make it manageable.” High-Risk Breast 
Lifetime Clinic Participant 5 shared how the clinic helped provide peace of mind and 
reduction of anxiety. Genetics Management Clinic Participant 1 felt that she was 
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confident that she was doing everything to prevent the return of cancer, and Genetics 
Management Clinic Participant 4 echoed this sentiment, describing how the clinic helped 
make the process a lot easier and less stressful.  
2.5.2 Specialized Management Clinic for Healthcare Needs 
Previvors without access to a specialized management clinic often rely on their 
current healthcare providers (primary care physicians, OB/GYNs, etc.) for care related to 
their increased cancer risk. Review of the literature suggests that these healthcare 
providers often lack the confidence regarding management guidelines to effectively care 
for these patients (Dekanek et. al., 2019). In fact, Dekanek and colleagues (2019) 
surveyed 86 OB/GYN and family practice physicians and found that only 44% of 
providers surveyed felt somewhat confident in discussing BRCA management guidelines, 
and no providers felt completely confident in doing so.  
 Participants in our study were asked to rank their agreement with the following 
statement: “I feel that my healthcare providers (primary care physician, obstetrician, 
gynecologist, etc.) have expert knowledge about the cancer screenings recommended for 
me” (Prisma Health-Midlands Survey). No participants indicated that they strongly 
agreed with the statement, further supporting previous literature that suggests that 
healthcare providers may require additional education about hereditary cancer and 
familial cancer and how to care for these patients. This finding again points to the need 
for a specialized management clinic, with providers who have expert knowledge in 
genetics and previvorship. 
 A study by Dean and Davidson (2018) discussed how previvors cope with 
uncertainty related to their increased risk for cancer and how they navigate care. One 
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common theme they identified among previvors was feeling that their experiences with 
healthcare providers were overwhelming. This feeling was not simply due to the 
management recommendations associated with the visit but also connected with the fact 
that previvors are sometimes burdened with the task of educating the provider about their 
risk and management (Dean & Davidson, 2018). Prisma Health-Midlands Participant 3 
experienced this lack of provider education and described how challenging it was to 
broach the subject with her physician because she felt it was uncomfortable to question 
the authority of a physician. In this study, one previvor encountered a healthcare provider 
who did not understand her perception of her cancer risk which left her feeling 
invalidated when she asked her physician about the possibility of a risk-reducing 
mastectomy. While there was one participant that felt comfortable with the care given by 
their healthcare provider, this was not the majority opinion. Therefore, these experiences 
highlight previvors’ need to advocate for themselves in the healthcare community, 
standing up for the care that they need. 
Participants with access to a specialized management clinic (either the Genetics 
Management Clinic or High-Risk Breast Lifetime Clinic) expressed high levels of 
satisfaction with their experience at the clinic, especially in regard to the simplicity of the 
care they received. Although receiving the initial risk assessment and management plan 
can be quite overwhelming, participants expressed that once established in the clinic, care 
became much easier. Goh and Spiegelman (2020) found that scheduling difficulties were 
a major factor prohibiting previvors’ proper adherence to the management guidelines. By 
establishing a specialized management clinic, this barrier was reduced (if not eliminated) 
with all coordination of appointments for screening or clinical evaluation being handled 
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by one clinic. Other studies found that insurance coverage for surveillance was a barrier 
to adherence; however, our participants did not express concerns with insurance 
coverage, possibly due to the coordination of the management clinic (Dean et. al., 2017). 
A specialized management clinic would include psychosocial support, 
management information, and updates on genetics. All six participants from the Prisma 
Health-Midlands clinic indicated they would be interested in attending a specialized 
management clinic for previvors if one were to be established. Although exact logistical 
details will depend on clinic staffing and location-dependent requirements, participants 
indicated several important services to be included in a management clinic. These 
integral features included access to a specialist with expertise in genetics, a system in 
place to be notified of changes to risk or management, and a place where previvors can 
ask questions. 
Participants described the need for a specialist in genetics and oncology to be 
involved in their care (Prisma Health-Midlands Participants 3 & 4), as Prisma Health-
Midlands Participant 3 sought access to providers who understood risks specific to her 
genetic mutation. This desire for a specialist’s involvement in a management clinic may 
again relate back to the fact that general practitioners may not be confident in providing 
care to previvors and, as a result, previvors’ care may not be sufficiently attended to 
(Dekanek et. al., 2019). This likely is of no fault of general practitioners but may stem 
from inadequate provider education regarding hereditary cancer and familial risks that 
reduces the confidence of these healthcare workers. A dedicated clinic for these 
individuals could provide a solution to a lack of access to educated providers without the 
need to provide mass education.  
 47 
This benefit was observed in our study with those who have access to a 
specialized management clinic. The patients were able to be seen for care quickly by 
multiple different providers, and any delay in care was prevented as much as possible. 
Genetics Management Clinic Participant 4 explained that she probably would have gone 
to different providers (breast, gastroenterology, etc.) in a prioritized manner over a period 
of time, but that it would not have been expedited like it was in the Genetics Management 
Clinic. Once theoretical plans have been put into action by the management clinic, 
previvors begin their journey towards cancer prevention and risk-reduction. 
 In addition to desiring a thorough education from someone who understands their 
exact mutation, participants also seek a clinic organized in such a way that they will be 
notified of any important changes to their risk status. As the genetics behind hereditary 
cancer continue to be researched, cancer risks and management recommendations may be 
updated. The NCCN publishes updated guidelines for genetic and familial high-risk care 
on a regular basis, often updating minor details, but occasionally altering cancer risk 
estimates or recommended screening strategies or risk-reduction methodology (NCCN, 
2020). Other research studies or clinical trials may offer specific information for 
previvors that individuals may not have access to on their own but would value learning 
about from a trusted healthcare provider. Prisma Health-Midlands Participant 1 described 
access to research as a major benefit of the CHEK2 Facebook group. It is possible that 
access to such research shared by a healthcare provider may be of even greater benefit if 
coupled with a simplified explanation. 
 Lastly, participants desired a clinic that gave them the opportunity to ask 
questions about their cancer risks and recommended management. Logistical questions 
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about screening, risk-reducing surgeries, and providers familiar with genetics were 
common concerns of participants. For example, one participant was interested in more 
information about recommended providers or clinics and where to go for care (Prisma 
Health-Midlands Participant 1). Although there are many factors that influence a patient’s 
care choices (for example, age, parental status, level of psychological distress, perceived 
family support, experienced medical uncertainty), patients require a clinic staffed with a 
provider able to answer their questions and assist in facilitating decision-making with 
these factors taken into account (Hesse-Biber & An, 2016).  
Participants of the Genetics Management Clinic and High-Risk Breast Lifetime 
Clinic felt that they were provided all information needed to make informed decisions 
regarding their care. Cancer prevention and risk-reduction comes with many nuances and 
options, which participants appreciated the opportunity to discuss with a specialized 
provider. When asked about the most valuable service provided by the clinic, Genetics 
Management Clinic Participant 5 stated: 
Education about the gene mutations as related to what it means and actions to take 
that can reduce your risk. I felt I could be proactive in reducing my cancer risks 
and that gave me some sense of control and a plan. After having my world turned 
upside down with a cancer diagnosis that was very helpful to me. (Genetics 
Management Clinic Participant 5) 
Providers in the clinic could help patients balance logical and emotional decision-making 
styles and assist the patient in coming to a decision they are satisfied with (Dean & 
Rauscher, 2017). For example, the provider could discuss the options of risk-reducing 
mastectomy or oophorectomy, and the potential effects it could have on patient quality of 
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life and family dynamics in addition to lowering cancer risks (Alexandre et. al., 2017; 
Mahon, 2014). By having expert providers provide these services in place of the patient’s 
primary care physician or OB/GYN, general practitioners have reduced burden for 
counseling patients on risks and management they are not confident of, and patients 
receive care catered specifically to their needs (Dekanek et. al., 2019). 
2.5.3 Role of a Genetic Counselor 
Although not specifically seeking to look at patient satisfaction with genetic 
counseling, this study found that participants were highly satisfied with the level of 
information provided to them by genetics professional. Many participants first learned of 
their previvor status from a genetic counselor, and participants expressed the benefits of 
meeting with a genetic counselor. Participants indicated that they felt supported 
throughout the testing process and were pleased with the information provided to them by 
their genetic counselor, stating that it helped them feel more prepared and increased their 
ability to be proactive regarding their risk. 
This high satisfaction with genetic counselors echoes previous research on patient 
satisfaction with genetic counseling (Sagi et. al., 1998). After genetic counseling, patients 
better understood the link between genetics and cancer, received answers to their 
questions, and felt confident in their plan for follow-up (Sagi et. al., 1998). Genetic 
counselors’ ability to break down complex scientific material in layman’s terms, coupled 
with a focus on psychosocial considerations associated with hereditary cancer testing, 
allows for increased patient satisfaction. Although participants were highly satisfied with 
their initial genetic counseling visit, it is evident from the survey responses that patients 
would like additional follow-up regarding their high-risk status, whether due to family 
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history or a genetic mutation. This supports the role of a genetic counselor in a 
specialized management clinic.  
2.6 Study Limitations 
 A major limitation of this study is the lack of participants who responded to the 
survey invitations and semi-structured phone interviews. Possible explanations for this 
may be due to the nature of sending research study invitations by mail, especially 
considering participants had no notification prior to receiving a letter that they would be 
contacted. Furthermore, it is possible that patients who are several years out from their 
initial appointment with the genetic counselor would be less interested in participating in 
the study if they already have a management plan in place. Additionally, the majority of 
participants with hereditary cancer mutations carried a variant in either BRCA1 or 
BRCA2, the two genes in the study with the highest lifetime risk for breast cancer. It is 
possible that this sample is biased towards desiring a clinic due to their substantially 
increased risk, as individuals of the clinics with variants in genes with lower risk chose 
not to participate. It is however possible, that this finding could be due to mutations in 
these genes being the most common finding on hereditary breast cancer panels and 
clinical testing for these genes having been available for longer, implying more patients 
may have been identified with BRCA1 or BRCA2 variants. 
2.7 Future Research 
Further research is needed in the area of previvorship and the establishment and 
utility of specialized management clinics, particularly studying patient adherence to 
clinical guidelines once a patient is seen in a management clinic, exploring patient health 
outcomes of previvors within these clinics, and further exploration of the clinic model for 
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CHAPTER 3: CONCLUSIONS 
 This study explored patient satisfaction and approach to care for previvors with 
access to a specialized management clinic and for those without access. Overall, all 
participants without access to a management clinic desired the establishment of one in the 
Midlands region, particularly with the hope of connecting with a specialist in genetics, 
being notified of changes to cancer risks or management recommendations, and having 
an opportunity to get questions answered. Participants described their current framework 
of care which largely included online support groups, guidance from their general 
practitioner, and the need for self-advocacy within both the healthcare realm and with 
their family, friends, and society. In contrast, participants who had access to a 
management clinic, such as the Genetics Management Clinic or High-Risk Breast 
Lifetime Clinic expressed high levels of satisfaction with their care. These participants 
cited a simplified and efficient process, prevention of delay to care, access to all 
information needed to make informed decisions, and reduced stress as major benefits of 
the management clinic. Specialized management clinics are not only helpful in guiding 
patients and allowing unhindered access to resources and support, but it improves the 
overall psychological health of the patient, which may lead to better health outcomes. 
These findings further point to the necessity of specialized management clinics, specific 
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APPENDIX A: RECRUITMENT LETTER FOR  




You are receiving this letter because you underwent cancer genetic counseling with Prisma 
Health-USC Genetic Counseling, and we are interested in creating a clinic that could assist in 
your healthcare. We are looking into the development of a clinic that would allow individuals 
with an increased risk of cancer to be seen by one healthcare practitioner who would oversee 
all the screening required because of that risk. To assess patient interest in this service, we are 
asking former patients to complete a survey. Through the information collected, we hope to 
provide better care for our patients. 
 
The study involves completing an online survey. At the completion of the survey, you will be 
given the option for a follow-up telephone interview. The survey is available online through 
Qualtrics and should take no more than 15 minutes to complete. The survey involves 
questions about your understanding of your predisposition for cancer, how you are currently 
receiving care, and your level of interest in the establishment of a new clinic for your cancer 
management. Participation is completely confidential. Data from the study will be stored in a 
secure location, will not be placed in your health record nor linked to your name, and will be 
destroyed at the completion of the study. The phone interviews will be recorded for analysis 
by the research team, but all information that you provide will be kept confidential. The 
results of the study may be published or presented; however, your identity will remain 
anonymous. This study is completely voluntary, and there are no negative consequences 
should you withdraw from the study.  
 
This study is a University of South Carolina Master in Genetic Counseling student thesis 
project. Maddie Tjoelker is completing her master’s degree and is conducting research on 
how individuals with a family history of cancer access screening and management.  
 
If you are interested in taking this survey, please enter the following link into your internet 













Your involvement in this study will help healthcare providers best serve their patients and 
give easier access to much-needed services. If you have any questions regarding the study or 





[GENETIC COUNSELOR], MS, CGC Maddie Tjoelker 
[PHONE NUMBER]    (803) 386-7302 

















APPENDIX B: RECRUITMENT LETTER FOR PRISMA HEALTH-UPSTATE 




You are receiving this letter because you have been seen at the Prisma Health Genetics 
Management Clinic, and we are interested in hearing your feedback. To assess patient 
satisfaction in this service, we are asking patients to complete a survey. Through the 
information collected, we hope to provide better care for our patients. 
 
The study involves completing an online survey. At the completion of the survey, you 
will be given the option for a follow-up telephone interview. The survey is available 
online through Qualtrics and should take no more than 15 minutes to complete. The 
survey involves questions about your understanding of your predisposition for cancer, 
how you are currently receiving care, and your level of satisfaction in the care you have 
received at the Genetics Management Clinic. Participation is completely confidential. 
Data from the study will be stored in a secure location, will not be placed in your health 
record nor linked to your name, and will be destroyed at the completion of the study. The 
phone interviews will be recorded for analysis by the research team, but all information 
that you provide will be kept confidential. The results of the study may be published or 
presented; however, your identity will remain anonymous. This study is completely 
voluntary, and there are no negative consequences should you withdraw from the study.  
 
This study is a University of South Carolina Master in Genetic Counseling student thesis 
project. Maddie Tjoelker is completing her master’s degree and is conducting research on 
how individuals with a family history of cancer access screening and management.  
 
If you are interested in taking this survey, please enter the following link into your 
internet browser on your computer, smart phone, or tablet. You may also scan the QR 







Your involvement in this study will help healthcare providers best serve their patients and 
give easier access to much-needed services. If you have any questions regarding the study 
or trouble accessing the survey, please reach out to myself or to Maddie Tjoelker. Thank 




LeAnn Perkins, MSN, FNP-BC  Maddie Tjoelker 
(864) 455-1346    (803) 386-7302 




















APPENDIX C: RECRUITMENT LETTER FOR PRISMA HEALTH-UPSTATE  




You are receiving this letter because you have been seen at the Prisma Health High-Risk 
Breast Lifetime Clinic, and we are interested in hearing your feedback. To assess patient 
satisfaction in this service, we are asking patients to complete a survey. Through the 
information collected, we hope to provide better care for our patients. 
 
The study involves completing an online survey. At the completion of the survey, you 
will be given the option for a follow-up telephone interview. The survey is available 
online through Qualtrics and should take no more than 15 minutes to complete. The 
survey involves questions about your understanding of your predisposition for cancer, 
how you are currently receiving care, and your level of satisfaction in the care you have 
received at the High-Risk Breast Lifetime Clinic. Participation is completely confidential. 
Data from the study will be stored in a secure location, will not be placed in your health 
record nor linked to your name, and will be destroyed at the completion of the study. The 
phone interviews will be recorded for analysis by the research team, but all information 
that you provide will be kept confidential. The results of the study may be published or 
presented; however, your identity will remain anonymous. This study is completely 
voluntary, and there are no negative consequences should you withdraw from the study.  
 
This study is a University of South Carolina Master in Genetic Counseling student thesis 
project. Maddie Tjoelker is completing her master’s degree and is conducting research on 
how individuals with a family history of cancer access screening and management.  
 
If you are interested in taking this survey, please enter the following link into your 
internet browser on your computer, smart phone, or tablet. You may also scan the QR 






Your involvement in this study will help healthcare providers best serve their patients and 
give easier access to much-needed services. If you have any questions regarding the study 
or trouble accessing the survey, please reach out to myself or to Maddie Tjoelker. Thank 




LeAnn Perkins, MSN, FNP-BC  Maddie Tjoelker 
(864) 455-1346    (803) 386-7302 

















APPENDIX D: SURVEY QUESTIONS FOR  
PRISMA HEALTH-MIDLANDS PARTICIPANTS 
 
Thank you for your participation in our study. All responses will be kept confidential and 
anonymous. In order to begin the survey, please indicate whether you consent to 
participating in our study. 
a. I consent 
b. I do not consent 
 
1. Please select your gender 
a. Male 
b. Female 
c. Prefer not to answer 
 







g. Over 70 
 




FOR MUTATION-POSITIVE PARTICIPANTS 
4. If yes, which gene? 
 
5. Have you been diagnosed with cancer? 
 a. Yes 
 b. No 
 
Please rate the following statements: 
6. I feel I have adequate knowledge about my cancer risk and am able to manage my 
personal healthcare to meet the recommendations. 
 a. Strongly disagree 
 b. Somewhat disagree
 64 
 c. Neither agree nor disagree
d. Somewhat agree 
 e. Strongly agree 
Comments on Question 6: 
 
7. I feel that my healthcare providers (primary care physician, obstetrician, gynecologist, 
etc.) have expert knowledge about the cancer screenings recommended for me. 
 a. Strongly disagree 
 b. Somewhat disagree 
 c. Neither agree nor disagree 
 d. Somewhat agree 
 e. Strongly agree 
Comments on Question 7: 
 
8. I have difficulty getting insurance coverage for the recommended cancer screenings. 
a. Strongly disagree 
 b. Somewhat disagree 
 c. Neither agree nor disagree 
 d. Somewhat agree 
 e. Strongly agree 
Comments on Question 8: 
 
9. Some institutions have set up clinics designed to assist individuals who carry a positive 
mutation in a hereditary cancer gene get the recommended screenings and management. 
How interested would you be in attending this clinic if it were created at Prisma Health 
Richland? 
 a. Not at all interested 
 b. Likely not interested 
 c. Neutral 
 d. Somewhat interested 
 e. Very interested 
 
10. Click and drag the following selections to rank the following services based on how 
important their incorporation into such a clinic is to you, with 1 being most important and 
6 being least important. 
• Cancer screenings (mammograms, breast MRI, etc.) 
• Psychosocial support 
• Genetic counseling 
• Nutritional services 
• Oncology 
• Plastic surgery 
 
11. Are there any additional services you would like to be included in this clinic? 
 
12. How often would you want to attend this type of clinic? 
 a. Only once 
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 b. Every 5 years 
 c. Every 2 years 
 d. Every year 
 e. Every 6 months 
 f. Other (please specify) 
 
13. Based on this conversation, what other thoughts do you have regarding the 
establishment of this type of clinic? 
 
FOR HIGH-RISK PARTICIPANTS 
4. Have you been diagnosed with cancer? 
 a. Yes 
 b. No 
 
5. Have you ever been told that you are at high risk for breast cancer? 
 a. Yes 
 b. No 
 c. Not sure 
 
6. Have you ever been told to do more breast cancer screening than an annual 
mammogram (such as breast MRI annually)? 
 a. Yes 
 b. No 
 c. Not sure 
 
Please rate the following statements: 
7. I feel I have adequate knowledge about my cancer risk and am able to manage my 
personal healthcare to meet the recommendations. 
 a. Strongly disagree 
 b. Somewhat disagree 
 c. Neither agree nor disagree 
 d. Somewhat agree 
 e. Strongly agree 
Comments on Question 7: 
 
8. I feel that my healthcare providers (primary care physician, obstetrician, gynecologist, 
etc.) have expert knowledge 
a. Strongly disagree 
 b. Somewhat disagree 
 c. Neither agree nor disagree 
 d. Somewhat agree 
 e. Strongly agree 
Comments on Question 8: 
 
9. I have difficulty getting insurance coverage for the recommended cancer screenings. 
a. Strongly disagree 
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 b. Somewhat disagree 
 c. Neither agree nor disagree 
 d. Somewhat agree 
 e. Strongly agree 
Comments on Question 9: 
 
10. Some institutions have set up clinics designed to help individuals who are at a higher 
risk for developing breast cancer get the recommended screenings. How interested would 
you be in attending this clinic if it were created at Prisma Health Richland? 
a. Not at all interested 
b. Likely not interested 
 c. Neutral 
 d. Somewhat interested 
 e. Very interested 
Comments on Question 10: 
 
11. Click and drag the following selections to rank the following services based on how 
important their incorporation into such a clinic is to you, with 1 being most important and 
6 being least important. 
• Cancer screenings (mammograms, breast MRI, etc.) 
• Psychosocial support 
• Genetic counseling 
• Nutritional services 
• Oncology 
• Plastic surgery 
 
12. Are there any other services that you would want to be offered at this clinic? 
 
13. How often would you want to attend this type of clinic? 
 a. Only once 
 b. Every 5 years 
 c. Every 2 years 
 d. Every year 
 e. Every 6 months 
 f. Other (please specify) 
 
14. Based on this conversation, what other thoughts do you have regarding the 
establishment of this type of clinic? 
 
FOR BOTH GROUPS: [At the completion of the survey] We want to hear more about 
your personal experience getting care and your level of interest in the establishment of 
this new clinic. If you would be willing to complete a follow-up telephone interview with 
Maddie Tjoelker, the primary investigator on this project, please fill in your telephone 




APPENDIX E: SURVEY QUESTIONS FOR PRISMA HEALTH-UPSTATE 
GENETICS MANAGEMENT CLINIC PARTICIPANTS 
 
Thank you for your participation in our study. All responses will be kept confidential and 
anonymous. In order to begin the survey, please indicate whether you consent to 
participating in our study. 
a. I consent 
b. I do not consent 
 














3. When did you have genetic testing? 
a. Less than 6 months ago 
b. 6-12 months ago 
c. 12-18 months ago 
d. 18-24 months ago 
e. Over 24 months ago 
 
4. When did you first begin attending the Genetics Management Clinic? 
a. Less than 6 months ago 
b. 6-12 months ago 
c. 12-18 months ago 
d. 18-24 months ago 
e. Over 24 months ago
 
 





6. On a scale from 1-10, with 1 being not at all satisfied and 10 being very satisfied, 
how satisfied are you with the services from the Genetics Management Clinic? 
 
7. Has getting screenings for your cancer risk gotten easier since going to the 
Genetics Management Clinic? 
a. Yes 
b. No 
c. Not sure 
Comments on Question 7: 
 
8. How often do you attend the Genetics Management Clinic?  
a. Less than once a year 
b. Once a year 
c. More than once a year 
 
9. Do you feel this is too often or not enough? 
 
10. What do you think is the most valuable service provided by the Genetics 
Management Clinic?  
 
11. Would you recommend this clinic to others? 
 
12. Is there anything that you wish would be added to the offerings of this clinic? 
(e.g., psychology, nutrition, etc.) 
 
[At completion of the survey] We want to hear more about your personal experience 
getting care at the Genetics Management Clinic. If you would be willing to complete a 
follow-up telephone interview with Maddie Tjoelker, the primary investigator on this 
















APPENDIX F: SURVEY QUESTIONS FOR PRISMA HEALTH-UPSTATE 
HIGH-RISK BREAST LIFETIME CLINIC PARTICIPANTS 
 
Thank you for your participation in our study. All responses will be kept confidential and 
anonymous. In order to begin the survey, please indicate whether you consent to 
participating in our study. 
a. I consent 
b. I do not consent 
 
1. When did you first begin attending the High-Risk Breast Lifetime Clinic? 
a. Less than 6 months ago 
b. 6-12 months ago 
c. 12-18 months ago 
d. 18-24 months ago 
e. More than 24 month ago 
 
2. What made you decide to attend the High-Risk Breast Lifetime Clinic? 
 
3. How often do you attend this clinic? 
a. Every 3 months 
b. Every 6 months 
c. Every 12 months 
d. Every 18 months 
e. Every 24 months 
f. Other (please specify) 
 
4. On a scale from 1-10, with 1 being not at all satisfied and 10 being very satisfied, 
how satisfied are you with the services provided by the High-Risk Breast Lifetime 
Clinic? 
 
5. Has getting mammograms and breast MRIs gotten easier since attending this clinic? 
a. Yes 
b. No 
c. Not sure 
Comments on Question 5: 
6. What do you think is the most valuable service provided by the High-Risk Breast 
Lifetime Clinic?
 
7. Is there anything that you wish would be added to the offerings of this clinic? 
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[At completion of the survey] We are interested in hearing more about your personal 
experience with the High-Risk Breast Lifetime Clinic. If you would be willing to 
complete a follow-up telephone interview with Maddie Tjoelker, the primary investigator 
on this project, please fill in your telephone number below, otherwise enter N/A to 








































APPENDIX G: PRISMA HEALTH-MIDLANDS SERVICE PREFERENCES 
 
Table G.1 Service Preferences Frequencies 
FREQUENCIES 
SERVICE RANK 
 1 2 3 4 5 6 
Cancer 
Screenings 
5 1 0 0 0 0 
Psychological 
Support 
0 0 1 1 2 2 
Genetic 
Counseling 
1 3 1 0 0 1 
Nutritional 
Services 
0 1 2 2 0 1 
Oncology 
 
0 1 1 2 1 1 
Plastic  
Surgery 
0 0 1 1 3 1 
 





 Total Rank 




Genetic Counseling 26 2 
Nutritional Services 20 3 
Oncology 18 4 
Plastic Surgery 14 5 
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Ranked Preferences of Services -
Midlands
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APPENDIX H: GENETICS MANAGEMENT CLINIC PARTICIPANT DATA 
Table H.1 Genetics Management Clinic Participant Data 
Clinical Information and Attendance 
 N Frequency 
When did you have genetic testing? 
Less than 6 months ago 0 0% 
6-12 months ago 1 10% 
12-18 months ago 1 10% 
18-24 months ago 3 30% 
Over 24 months ago 5 50% 
When did you first begin attending the Genetics Management Clinic? 
Less than 6 months ago 0 0% 
6-12 months ago 1 10% 
12-18 months ago 1 10% 
18-24 months ago 4 40% 
Over 24 months ago 4 40% 
Have you been diagnosed with cancer? (Not including non-melanoma skin cancer) 
Yes 6 60% 
No 4 40% 
Has getting screenings for your cancer risk gotten easier since going to the Genetics 
Management Clinic? 
Yes 5 50% 
No 0 0% 
Not sure 5 50% 
How often do you attend the Genetics Management Clinic? 
Less than once a year 1 10% 
Once a year 9 90% 








APPENDIX I: HIGH-RISK BREAST LIFETIME CLINIC PARTICIPANT DATA 
Table I.1 High-Risk Breast Lifetime Clinic Participant Data 
Clinical Information and Attendance 
 N Frequency 
When did you first begin attending the High-Risk Breast Lifetime Clinic? 
Less than 6 months ago 0 0% 
6-12 months ago 1 11.1% 
12-18 months ago 2 22.2% 
18-24 months ago 1 11.1% 
Over 24 months ago 5 55.6% 
How often do you attend the High-Risk Breast Lifetime Clinic? 
Every 6 months 4 50% 
Every 12 months 3 37.5% 
Other—No longer attend 1 12.5% 
On a scale from 0-10, with 0 being not at all satisfied and 10 being very satisfied, how 
satisfied are you with the services provided by the High-Risk Breast Lifetime Clinic? 
1 0 0% 
2 0 0% 
3 0 0% 
4 0 0% 
5 0 0% 
6 0 0% 
7 2 22.2% 
8 2 22.2% 
9 2 22.2% 
10 3 33.3% 
Has getting breast cancer screening (i.e., mammograms and breast MRIs) gotten easier 
since attending this clinic? 
Yes 6 66.7% 
No 2 22.2% 
Not sure 1 11.1% 
 
